Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation - - BioPharm International

ADVERTISEMENT

Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation



Cornerstone Pharmaceuticals, a cancer metabolism-based therapeutics company, has been granted orphan-drug designation by FDA for CPI-613, the company's altered energy metabolism directed (AEMD) drug candidate for treating myelodysplastic syndrome (MDS).

Cornerstone Pharmaceuticals previously received orphan-drug designation for the use of CPI-613 in the treatment of acute myeloid leukemia and pancreatic carcinoma. CPI-613 induces cancer-specific inhibition of pyruvate dehydrogenase and alpha ketoglutarate dehydrogenase, key mitochondrial enzymes involved in cancer-cell metabolism. CPI-613 is currently being evaluated in Phase I, I/II, and Phase II trials in hematologic malignancies and solid tumors.

Source: Cornerstone Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here